IDXX — IDEXX Laboratories Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedLarge CapHigh Flyer
- $39.71bn
- $40.40bn
- $3.37bn
- 98
- 10
- 83
- 69
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 44.43 | ||
| PEG Ratio (f) | 4.35 | ||
| EPS Growth (f) | 11.37% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 30.61 | ||
| Price to Tang. Book | 46.8 | ||
| Price to Free Cashflow | 58.42 | ||
| Price to Sales | 11.07 | ||
| EV to EBITDA | 33.89 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 50.96% | ||
| Return on Equity | 92.79% | ||
| Operating Margin | 30.06% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2,213.24 | 2,406.91 | 2,706.66 | 3,215.36 | 3,367.32 | 3,644.02 | 3,947.85 | 11.33% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +31.23 | +13.37 | +37.82 | +28.5 | -7.23 | +22.61 | +10.36 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. It also offers human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment provides products and services for veterinarians and the biomedical research community, primarily related to diagnostics and information management. The Water segment provides testing solutions for the detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry. The Company has sales offices outside the United States in all regions, including Africa, Asia Pacific, Canada, Europe, the Middle East, and Latin America.
Directors
- Lawrence Kingsley NEC (58)
- Jonathan Mazelsky PRE (60)
- Brian McKeon CFO (58)
- Giovani Twigge CHO (57)
- Tina Hunt EVP (53)
- Michael Lane EVP (53)
- James Polewaczyk EVP (58)
- Kathy Turner SVP (57)
- Sharon Underberg SVP (59)
- Jonathan Ayers DRC (65)
- Bruce Claflin IND (69)
- Asha Collins IND (45)
- Stuart Essig IND (58)
- Daniel Junius IND (68)
- Sam Samad IND (52)
- M. Anne Szostak IND (70)
- Sophie Vandebroek IND (59)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- December 19th, 1983
- Public Since
- June 21st, 1991
- No. of Shareholders
- 390
- No. of Employees
- 10,780
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 83,051,702
- Address
- One Idexx Drive, WESTBROOK, 04092-2041
- Web
- https://www.idexx.com/
- Phone
- +1 2075560300
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for IDXX
Q1 2024 IDEXX Laboratories Inc Earnings Release
IDEXX Laboratories Inc Annual Shareholders Meeting
Similar to IDXX
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the IDEXX Laboratories share price?
As of Today at 18:11 UTC, shares in IDEXX Laboratories are trading at $478.18. This share price information is delayed by 15 minutes.
How has the IDEXX Laboratories share price performed this year?
Shares in IDEXX Laboratories last closed at $478.18 and the price had moved by +14.8% over the past 365 days. In terms of relative price strength the IDEXX Laboratories share price has outperformed the S&P500 Index by +1.37% over the past year.
What are the analyst and broker recommendations for IDEXX Laboratories?
The overall consensus recommendation for IDEXX Laboratories is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the IDEXX Laboratories dividend yield?
IDEXX Laboratories does not currently pay a dividend.
Does IDEXX Laboratories pay a dividend?
IDEXX Laboratories does not currently pay a dividend.
When does IDEXX Laboratories next pay dividends?
IDEXX Laboratories does not currently pay a dividend.
How do I buy IDEXX Laboratories shares?
To buy shares in IDEXX Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of IDEXX Laboratories?
As of the previous close price of $478.18, shares in IDEXX Laboratories had a market capitalisation of $39.71bn.
Where are IDEXX Laboratories shares listed?
Here are the trading details for IDEXX Laboratories:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: IDXX
What kind of share is IDEXX Laboratories?
Based on an overall assessment of its quality, value and momentum IDEXX Laboratories is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a IDEXX Laboratories share price forecast for 2023?
The analyst consensus target price for shares in IDEXX Laboratories is $515.25. That is 7.75% above the last closing price of $478.18.
Analysts covering IDEXX Laboratories currently have a consensus Earnings Per Share (EPS) forecast of $9.84 for the next financial year.
What is the trend in the IDEXX Laboratories share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IDEXX Laboratories. Over the past six months, its share price has underperformed the S&P500 Index by -5.94%.
As of the last closing price of $478.18, shares in IDEXX Laboratories were trading +0.26% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the IDEXX Laboratories PE Ratio?
The IDEXX Laboratories PE ratio based on its reported earnings over the past 12 months is 44.43. The shares last closed at $478.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of IDEXX Laboratories?
IDEXX Laboratories' management team is headed by:
- Lawrence Kingsley - NEC
- Jonathan Mazelsky - PRE
- Brian McKeon - CFO
- Giovani Twigge - CHO
- Tina Hunt - EVP
- Michael Lane - EVP
- James Polewaczyk - EVP
- Kathy Turner - SVP
- Sharon Underberg - SVP
- Jonathan Ayers - DRC
- Bruce Claflin - IND
- Asha Collins - IND
- Stuart Essig - IND
- Daniel Junius - IND
- Sam Samad - IND
- M. Anne Szostak - IND
- Sophie Vandebroek - IND